These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20526388)

  • 1. The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: results of the ACCEL-GENERIC study.
    Jeong YH; Koh JS; Kang MK; Ahn YJ; Kim IS; Park Y; Hwang SJ; Kwak CH; Hwang JY
    Korean J Intern Med; 2010 Jun; 25(2):154-61. PubMed ID: 20526388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel.
    Bouman HJ; Parlak E; van Werkum JW; Breet NJ; ten Cate H; Hackeng CM; ten Berg JM; Taubert D
    J Thromb Haemost; 2010 Mar; 8(3):482-8. PubMed ID: 20040042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the antiplatelet effect of two clopidogrel bisulfate formulations: Plavix and generic-Egitromb.
    Komosa A; Siller-Matula JM; Kowal J; Lesiak M; Siniawski A; Mączyński M; Michalak M; Mularek-Kubzdela T; Grajek S
    Platelets; 2015; 26(1):43-7. PubMed ID: 24499166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
    Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl ML
    JACC Cardiovasc Interv; 2008 Dec; 1(6):620-7. PubMed ID: 19463375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Point-of-care measurements of platelet inhibition after clopidogrel loading in patients with acute coronary syndrome: comparison of generic and branded clopidogrel bisulfate.
    Seo KW; Tahk SJ; Yang HM; Yoon MH; Shin JH; Choi SY; Lim HS; Hwang GS; Choi BJ; Park JS; Shin JS; Lee YH; Choi YW; Park SJ; Jin XJ
    Clin Ther; 2014 Nov; 36(11):1588-94. PubMed ID: 25218311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of original and generic clopidogrel 600 mg loading dose in the patients who planned undergoing coronary angiography.
    Srimahachota S; Rojnuckarin P; Udayachalerm W; Buddhari W; Chaipromprasit J; Lertsuwunseri V; Akkawat B; Jirapattrathamrong S
    J Med Assoc Thai; 2012 Dec; 95(12):1495-500. PubMed ID: 23390778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
    Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
    Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    J Thromb Haemost; 2010 Jan; 8(1):37-42. PubMed ID: 19818001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal variability in the antiplatelet effects of clopidogrel and aspirin after elective drug-eluting stent implantation. An ADAPT-DES substudy.
    Nührenberg TG; Stratz C; Leggewie S; Hochholzer W; Valina CM; Gick M; Kirtane AJ; Stone GW; Neumann FJ; Trenk D
    Thromb Haemost; 2015 Nov; 114(5):1020-7. PubMed ID: 26305340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel.
    Oestreich JH; Holt J; Dunn SP; Smyth SS; Campbell CL; Charnigo R; Akers WS; Steinhubl SR
    Coron Artery Dis; 2009 May; 20(3):207-13. PubMed ID: 19318928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study.
    Jeong YH; Hwang JY; Kim IS; Park Y; Hwang SJ; Lee SW; Kwak CH; Park SW
    Circ Cardiovasc Interv; 2010 Feb; 3(1):17-26. PubMed ID: 20118150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study.
    Jeong YH; Lee SW; Choi BR; Kim IS; Seo MK; Kwak CH; Hwang JY; Park SW
    J Am Coll Cardiol; 2009 Mar; 53(13):1101-9. PubMed ID: 19324253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of 450-mg loading dose of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement.
    Fukushima K; Kobayashi Y; Kitahara H; Iwata Y; Kuroda N; Ooyama M; Nomura F; Komuro I
    Heart Vessels; 2010 May; 25(3):182-6. PubMed ID: 20512444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in Japanese patients with stable coronary artery disease.
    Nishi T; Ariyoshi N; Nakayama T; Fujimoto Y; Sugimoto K; Takahara M; Wakabayashi S; Koshizaka M; Hanaoka H; Kobayashi Y
    Circ J; 2015; 79(11):2439-44. PubMed ID: 26310876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of 150-mg vs 300-mg loading doses of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement.
    Fukushima K; Kobayashi Y; Kitahara H; Iwata Y; Nakayama T; Kuroda N; Ooyama M; Nomura F; Komuro I
    Circ J; 2008 Aug; 72(8):1282-4. PubMed ID: 18654014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.
    Aleil B; Jacquemin L; De Poli F; Zaehringer M; Collet JP; Montalescot G; Cazenave JP; Dickele MC; Monassier JP; Gachet C
    JACC Cardiovasc Interv; 2008 Dec; 1(6):631-8. PubMed ID: 19463377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
    Schäfer A; Weinberger S; Flierl U; Eigenthaler M; Störk S; Walter U; Ertl G; Bauersachs J
    Thromb Haemost; 2008 Oct; 100(4):618-25. PubMed ID: 18841284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
    Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
    Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the efficacy and tolerability of clopidogrel napadisilate in Korean patients with coronary stenting: a multicenter, prospective, open-label, randomized trial.
    Kim SH; Sung JH; Shin J; Lee HJ; Lee HS; Cho DK; Lim SW
    Curr Med Res Opin; 2015 Mar; 31(3):449-57. PubMed ID: 25586295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
    Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G
    Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.